<DOC>
	<DOCNO>NCT02010203</DOCNO>
	<brief_summary>This study two part study : Phase I Phase II . The Phase 1 portion open-label , safety study . Patients previously receive 3-6 instillation weekly intravesical Bacillus Calmette-Guerin ( BCG ) induction therapy ( standard care ) follow low dose intradermal ( 1*10^6 cell ) HS-410 monotherapy . In Phase 2 , patient assign treatment group base whether receive induction BCG typical post-TURBT window . If investigator plan administer BCG , patient randomize one three blind ( physician-patient ) , placebo-controlled group receive either intradermal placebo low dose ( 1*10^6 cell ) high dose ( 1*10^7 cell ) vesigenurtacel-L combination induction maintenance intravesical BCG . If patient receive BCG , enrol open-label , non-randomized group receive high dose ( 1*10^7 cell ) intradermal HS-410 monotherapy .</brief_summary>
	<brief_title>A Phase 1/2 Study HS-410 Patients With Non-Muscle Invasive Bladder Cancer After TURBT</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>BCG Vaccine</mesh_term>
	<criteria>Histologically cytologically confirm nonmuscle invasive bladder cancer [ Ta , T1 Tis ( CIS ) ] remove transurethral resection Either : ( ) highrisk disease , define T1 and/or highgrade and/or CIS ( ii ) intermediaterisk disease , define Ta lowgrade least 3 follow 4 risk factor : multiple tumor , tumor size &gt; 3cm , early recurrence ( &lt; 1 year previous staging procedure ) , recurrence frequency 12 month period Not receive bacillus CalmetteGuérin ( BCG ) complete previous BCG treatment &gt; 12 month prior baseline stag procedure . Phase 2 Arms 13 : Suitable receive 6week course BCG adjuvant setting within 6 week follow TURBT . Phase 2 Arm 4 : Suitable monotherapy vaccine administration postTURBT . For Phase 1 : Has previously receive 36 weekly dos BCG . Adequate laboratory parameter Human immunodeficiency virus ( HIV ) infection immunodeficiency disorder , either primary acquire Infections intercurrent illness require active therapy Any condition require active steroid immunosuppressive therapy Active malignancy within past 12 month except negligible risk metastasis death treat expect curative outcome . Prostate pelvic radiation within past 12 month Significant cardiac impairment Current alcohol chemical abuse , mental psychiatric condition preclude protocol compliance Pregnant nursing Allergy soy , egg , peanut product Receiving another investigational agent ( 30 day washout require prior first dose ) Neoadjuvant therapy prior baseline staging procedure current occurrence nonmuscle invasive bladder cancer Prior treatment cancer vaccine indication Prior vaccination BCG tuberculosis disease Prior splenectomy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>TURBT</keyword>
	<keyword>Bladder</keyword>
	<keyword>Cancer</keyword>
	<keyword>GP96</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Heat Biologics</keyword>
	<keyword>BCG</keyword>
	<keyword>Bacillus Calmette-Guerin</keyword>
	<keyword>Bacillus Calmette-Guérin</keyword>
</DOC>